Patent ID: 11859006
Assignee: DAIICHI SANKYO COMPANY, LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C

Claim 0:
1. A method for binding a mutated ALK2 in a subject, comprising:
administering to a subject that has an active mutation in ALK2 an anti-ALK2 antibody or an antigen-binding fragment thereof or a pharmaceutical composition comprising an anti-ALK2 antibody or an antigen-binding fragment thereof;
wherein the active mutation in ALK2 comprises at least one mutation selected from L196P, delP197_F198insL, R202I, R206H, Q207E, R258S, R258G, G325A, G328E, G328R, G328W, G356D, and R375P, relative to SEQ ID NO: 1, but does not have a mutation of an amino acid residue at position 330 of SEQ ID NO: 1,
wherein the subject has ectopic ossification or diffuse intrinsic pontine glioma (DIPG).